{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:41:57Z","timestamp":1791297717377,"version":"4.1.0"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>There continues to be uncertainty about the classification of available drugs for treating osteoporosis. We find that grouping them into anti-catabolic and anabolic classes based on the mechanisms of their action on bone remodeling and fracture reduction removes ambiguities and provides a relatively straightforward classification.<\/jats:p>\n               <jats:p>The recent introduction of teriparatide into clinical practice initiated the era of anabolic therapy for osteoporosis, but it is still unclear how to define an anabolic drug. All drugs that increase bone mass do so by affecting bone remodeling. When their mechanisms of action on bone remodeling and on fracture reduction are considered, we find that anti-osteoporotic drugs fall naturally into either anti-catabolic or anabolic classes. Anti-catabolic drugs increase bone strength and reduce fractures mainly by decreasing the number of bone multicellular units (BMUs). This reduces perforative resorption and preserves skeletal microarchitecture (by preventing further structural damage to trabecular bone and increased porosity in cortical bone induced by high bone remodeling). Reduction in bone remodeling by anti-catabolic drugs may increase bone mass moderately during the interval in which previously initiated BMUs are completing mineralization. Some anti-catabolic drugs may also enhance the formation phase of the remodeling cycle, but their major action is to reduce overall bone turnover (i.e., the number of BMUs in bone). In contrast, anabolic drugs increase bone strength and reduce fractures by substantially increasing bone mass as a result of an overall increase in the number of BMUs combined with a positive BMU balance (the magnitude of the formation phase is greater than that of the resorption phase). Some anabolic drugs also induce renewed modeling, increase periosteal apposition and repair of trabecular microstructure. We hope that this classification will serve as a starting point for continued discussion on the important issue of nomenclature.<\/jats:p>","DOI":"10.1359\/jbmr.041114","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T00:31:36Z","timestamp":1146097896000},"page":"177-184","source":"Crossref","is-referenced-by-count":296,"title":["Drugs Used to Treat Osteoporosis: The Critical Need for a Uniform Nomenclature Based on Their Action on Bone Remodeling"],"prefix":"10.1093","volume":"20","author":[{"given":"B Lawrence","family":"Riggs","sequence":"first","affiliation":[{"name":"Endocrine Research Unit, Division of Endocrinology and Metabolism, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Michael","family":"Parfitt","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Center for Osteoporosis and Metabolic Bone Diseases, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024013019224252700_bib1","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1056\/NEJM199003223221203","article-title":"Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis","volume":"322","author":"Riggs","year":"1990","journal-title":"N Engl J Med"},{"key":"2024013019224252700_bib2","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1172\/JCI118722","article-title":"Bisphosphonates: Mechanisms of action","volume":"97","author":"Rodan","year":"1996","journal-title":"J Clin Invest"},{"key":"2024013019224252700_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S8756-3282(01)00642-1","article-title":"Targeted and nontargeted bone remodeling: Relationship to basic multicellular unit origination and progression","volume":"30","author":"Parfitt","year":"2002","journal-title":"Bone"},{"key":"2024013019224252700_bib4","first-page":"469","volume-title":"Disorders of Bone and Mineral Metabolism","author":"Parfitt","year":"2002","edition":"2nd ed."},{"key":"2024013019224252700_bib5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/B978-012470862-4\/50020-9","volume-title":"Osteoporosis","author":"Bouxsein","year":"2001","edition":"2nd ed."},{"key":"2024013019224252700_bib6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/8756-3282(87)90074-3","article-title":"Biomechanical competence of vertebral trabecular bone in relation to ash density and age in normal individuals","volume":"8","author":"Mosekilde","year":"1987","journal-title":"Bone"},{"key":"2024013019224252700_bib7","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1359\/jbmr.2000.15.12.2297","article-title":"Structural trends in the aging femoral neck and proximal shaft: Analysis of the third national health and nutrition examination survey dual-energy x-ray absorptiometry data","volume":"15","author":"Beck","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2024013019224252700_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF02008077","article-title":"Variations in strength of vertebrae with age and their relation to osteoporosis","volume":"1","author":"Bell","year":"1967","journal-title":"Calcif Tissue Res"},{"key":"2024013019224252700_bib9","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1172\/JCI111096","article-title":"Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis","volume":"72","author":"Parfitt","year":"1983","journal-title":"J Clin Invest"},{"key":"2024013019224252700_bib10","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1359\/jbmr.1999.14.7.1217","article-title":"Hormone replacement therapy prevents osteoclastic hyperactivity: A histomorphometric study in early postmenopausal women","volume":"14","author":"Eriksen","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2024013019224252700_bib11","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women","volume":"337","author":"Delmas","year":"1997","journal-title":"N Engl J Med"},{"key":"2024013019224252700_bib12","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am J Med"},{"key":"2024013019224252700_bib13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1210\/edrv.23.4.0486","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis","volume":"23","author":"Osteoporosis","year":"2002","journal-title":"Endocr Rev"},{"key":"2024013019224252700_bib14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S8756-3282(00)00271-4","article-title":"Monitoring individual response to hormone replacement therapy with bone markers","volume":"26","author":"Delmas","year":"2000","journal-title":"Bone"},{"key":"2024013019224252700_bib15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut","year":"1995","journal-title":"Am J Med"},{"key":"2024013019224252700_bib16","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019224252700_bib17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"2024013019224252700_bib18","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis","volume":"100","author":"Chavassieux","year":"1997","journal-title":"J Clin Invest"},{"key":"2024013019224252700_bib19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s001980050194","article-title":"Bone remodeling and structure in postmenopausal women treated with long-term, high-dose estrogen therapy","volume":"10","author":"Vedi","year":"1999","journal-title":"Osteoporos Int"},{"key":"2024013019224252700_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-117-1-1","article-title":"Treatment of postmenopausal osteoporosis with transdermal estrogen","volume":"117","author":"Lufkin","year":"1992","journal-title":"Ann Intern Med"},{"key":"2024013019224252700_bib21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/jbmr.5650110203","article-title":"A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates","volume":"11","author":"Parfitt","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024013019224252700_bib22","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1172\/JCI0214538","article-title":"Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids","volume":"109","author":"Weinstein","year":"2002","journal-title":"J Clin Invest"},{"key":"2024013019224252700_bib23","first-page":"115","article-title":"Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis","volume":"21","author":"Manolagas","year":"2000","journal-title":"Endocr Rev"},{"key":"2024013019224252700_bib24","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/nm1096-1132","article-title":"Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta","volume":"2","author":"Hughes","year":"1996","journal-title":"Nat Med"},{"key":"2024013019224252700_bib25","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin","volume":"104","author":"Plotkin","year":"1999","journal-title":"J Clin Invest"},{"key":"2024013019224252700_bib26","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1172\/JCI10942","article-title":"Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men","volume":"106","author":"Falahati-Nini","year":"2000","journal-title":"J Clin Invest"},{"key":"2024013019224252700_bib27","doi-asserted-by":"crossref","first-page":"M266","DOI":"10.1093\/gerona\/56.5.M266","article-title":"Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels","volume":"56A","author":"Kenny","year":"2001","journal-title":"J Gerontol"},{"key":"2024013019224252700_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/jcem.87.1.8141","article-title":"Tibolone for postmenopausal women: Systematic review of randomized trials","volume":"87","author":"Modelska","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019224252700_bib29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fractue in women with postmenopausal osteoporosis","volume":"350","author":"Meunier","year":"2004","journal-title":"N Engl J Med"},{"key":"2024013019224252700_bib30","first-page":"273","article-title":"Morphologic basis of bone mineral measurements: Transient and steady state effects of treatment in osteoporosis","volume":"4","author":"Parfitt","year":"1980","journal-title":"Miner Electrolyte Metab"},{"key":"2024013019224252700_bib31","first-page":"164","volume-title":"Osteoporosis","author":"Parfitt","year":"1993"},{"key":"2024013019224252700_bib32","first-page":"13","author":"Riggs","year":"1993"},{"issue":"Suppl","key":"2024013019224252700_bib33","doi-asserted-by":"crossref","first-page":"197S","DOI":"10.1016\/8756-3282(95)00502-1","article-title":"Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy","volume":"18","author":"Riggs","year":"1996","journal-title":"Bone"},{"key":"2024013019224252700_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.2002.17.1.11","article-title":"Bone turnover matters: The raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density","volume":"17","author":"Riggs","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024013019224252700_bib35","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1359\/JBMR.0301243","article-title":"Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk","volume":"19","author":"Sarkar","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024013019224252700_bib36","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","article-title":"Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study","volume":"15","author":"Garnero","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2024013019224252700_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.2002.17.1.1","article-title":"Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy","volume":"17","author":"Sarkar","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2024013019224252700_bib38","volume-title":"Antifracture efficacy of risedronate: Prediction by change in bone resorption markers","author":"Eastell","year":"2002"},{"key":"2024013019224252700_bib39","volume-title":"Reduction in bone turnover predicts hip, non-spine, and vertebral fracture in alendronate treated women: The fracture intervention trial","author":"Bauer","year":"2002"},{"key":"2024013019224252700_bib40","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"2024013019224252700_bib41","first-page":"2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019224252700_bib42","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"key":"2024013019224252700_bib43","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI3914","article-title":"Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis","volume":"102","author":"Lane","year":"1998","journal-title":"J Clin Invest"},{"key":"2024013019224252700_bib44","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1210\/jc.2003-030768","article-title":"Efficacy and safety of human parathyroid hormone-(1\u201384) in increasing bone mineral density in postmenopausal osteoporosis","volume":"88","author":"Hodsman","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019224252700_bib45","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/8756-3282(93)90190-L","article-title":"Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: Evidence for de novo bone formation on quiescent cancellous surfaces","volume":"14","author":"Hodsman","year":"1993","journal-title":"Bone"},{"issue":"S1","key":"2024013019224252700_bib46","first-page":"S179","article-title":"PTH treatment directly stimulates bone formation in cancellous and cortical bone in humans","volume":"16","author":"Dempster","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024013019224252700_bib47","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1172\/JCI7991","article-title":"Stemming bone loss by suppressing apoptosis","volume":"104","author":"Hock","year":"1999","journal-title":"J Clin Invest"},{"key":"2024013019224252700_bib48","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI6610","article-title":"Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone","volume":"104","author":"Jilka","year":"1999","journal-title":"J Clin Invest"},{"key":"2024013019224252700_bib49","first-page":"S1","article-title":"Short term response to parathyroid hormone (1\u201334hPTH) in human iliac crest bone using a unique quadruple (double double) tetracycline labeling regimen and single biopsy","volume":"18","author":"Lindsay","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019224252700_bib50","author":"Parfitt","year":"2002"},{"key":"2024013019224252700_bib51","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/jbmr.5650071216","article-title":"Bone resorption and formation on the periosteal envelope of the ilium: A histomorphometric study in healthy women","volume":"7","author":"Balena","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2024013019224252700_bib52","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1210\/endo.136.8.7628403","article-title":"Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells","volume":"136","author":"Dobnig","year":"1995","journal-title":"Endocrinology"},{"key":"2024013019224252700_bib53","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study","volume":"16","author":"Dempster","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024013019224252700_bib54","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Recombinant human parathyroid hormone (1\u201334) [teriparatide] improves both cortical and cancellous bone structure","volume":"18","author":"Jiang","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"S1","key":"2024013019224252700_bib55","first-page":"S208","article-title":"Teriparatide (rhPTH(1\u201334) improves the structural geometry of the hip","volume":"17","author":"Uusi-Rasi","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2024013019224252700_bib56","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00198-002-1312-0","article-title":"Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis","volume":"14","author":"Rehman","year":"2003","journal-title":"Osteoporos Int"},{"key":"2024013019224252700_bib57","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1359\/jbmr.2003.18.3.406","article-title":"Growth hormone rising: Did we quit too quickly","volume":"18","author":"Rosen","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019224252700_bib58","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0169-6009(92)90789-G","article-title":"Bone hypertrophy and trabecular generation in Paget's disease and in fluoride-treated osteoporosis","volume":"17","author":"Aaron","year":"1992","journal-title":"Bone Miner"},{"key":"2024013019224252700_bib59","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S8756-3282(00)00430-0","article-title":"Treatment with human parathyroid hormone (1\u201334) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis)","volume":"28","author":"Jerome","year":"2001","journal-title":"Bone"},{"key":"2024013019224252700_bib60","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198606263142605","article-title":"Medical progress series: Involutional osteoporosis","volume":"314","author":"Riggs","year":"1986","journal-title":"N Engl J Med"},{"key":"2024013019224252700_bib61","first-page":"955","article-title":"Markers of bone turnover in hyperthyroidism and the effects of treatment","volume":"78","author":"Garnero","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019224252700_bib62","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s007760050054","article-title":"From Wolff's law to the mechanostat: A new \u201cface\u201d of physiology","volume":"3","author":"Frost","year":"1998","journal-title":"J Orthop Sci"},{"key":"2024013019224252700_bib63","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.1074935","article-title":"Reversal of bone loss in mice by nongenotropic signaling of sex steroids","volume":"298","author":"Kousteni","year":"2002","journal-title":"Science"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2FJBMR.041114","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/20\/2\/177\/56476623\/5650200201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/20\/2\/177\/56476623\/5650200201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:07:49Z","timestamp":1710342469000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/20\/2\/177-184\/7593001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,1]]},"references-count":63,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2005,2,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.041114","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,2,1]]},"published":{"date-parts":[[2005,2,1]]}}}